Simple Scoring System to Predict In-Hospital Mortality After Surgery for Infective Endocarditis

Giuseppe Gatti, Andrea Perrotti, Jean-François Obadia, Xavier Duval, Bernard Iung, François Alla, Catherine Chirouze, Christine Selton-Suty, Bruno Hoen, Gianfranco Sinagra, et al.

To cite this version:

Giuseppe Gatti, Andrea Perrotti, Jean-François Obadia, Xavier Duval, Bernard Iung, et al.. Simple Scoring System to Predict In-Hospital Mortality After Surgery for Infective Endocarditis. Journal of the American Heart Association, Wiley-Blackwell, 2017, 6 (7), pp.e004806. 10.1161/JAHA.116.004806. inserm-01572153

HAL Id: inserm-01572153
https://www.hal.inserm.fr/inserm-01572153
Submitted on 4 Aug 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Simple Scoring System to Predict In-Hospital Mortality After Surgery for Infective Endocarditis

Giuseppe Gatti, MD; Andrea Perrotti, MD; Jean-François Obadia, MD, PhD; Xavier Duval, MD, PhD; Bernard Iung, MD; François Alla, MD, PhD; Catherine Chirouze, MD, PhD; Christine Selton-Suty, MD, PhD; Bruno Hoen, MD, PhD; Gianfranco Sinagra, MD, FESC; François Delahaye, MD; Pierre Tattevin, MD; Vincent Le Moing, MD; Aniello Pappalardo, MD; Sidney Chocron, MD, PhD; on behalf of The Association for the Study and Prevention of Infective Endocarditis Study Group—Association pour l’Étude et la Prévention de l’Endocardite Infectieuse (AEPEI)*

**Background**—A specific scoring system is used to predict the risk of death postsurgery in patients with infective endocarditis (IE). The purpose of the present study was both to analyze the risk factors for in-hospital death, which complicates surgery for IE, and to create a mortality risk score based on the results of this analysis.

**Methods and Results**—Outcomes of 361 consecutive patients (mean age, 59.1±15.4 years) who had undergone surgery for IE in 8 European centers of cardiac surgery were recorded prospectively, and a risk factor analysis (multivariable logistic regression) for in-hospital death was performed. The discriminatory power of a new predictive scoring system was assessed with the receiver operating characteristic curve analysis. Score validation procedures were carried out. Fifty-six (15.5%) patients died postsurgery. BMI ≥27 kg/m² (odds ratio [OR], 1.79; P=0.049), estimated glomerular filtration rate <50 mL/min (OR, 3.52; P<0.0001), New York Heart Association class IV (OR, 2.11; P=0.024), systolic pulmonary artery pressure >55 mm Hg (OR, 1.78; P=0.032), and critical state (OR, 2.37; P=0.017) were independent predictors of in-hospital death. A scoring system was devised to predict in-hospital death postsurgery for IE (area under the receiver operating characteristic curve, 0.780; 95% CI, 0.734–0.822). The score performed better than 5 of 6 scoring systems for in-hospital death after cardiac surgery that were considered.

**Conclusions**—A simple scoring system based on risk factors for in-hospital death was specifically created to predict mortality risk postsurgery in patients with IE. (J Am Heart Assoc. 2017;6:e004806. DOI: 10.1161/JAHA.116.004806.)

**Key Words:** cardiac valvular surgery • critical care • infective endocarditis • mortality • predictors • pulmonary hypertension • quality control • treatment outcome

Outcome in patients with infective endocarditis (IE) is a complex process, mediated by the immune system, and a function of interactions between patient-related factors (eg, demographic data, risk factors for cardiovascular disease, underlying cardiac disease, and comorbidities) and the properties of the causal agent (eg, nature, virulence, and antibiotic resistance). In 25% to 30% of cases, medical treatment alone is inadequate and must be combined with surgery, which aims to control infection by debridement and removal of necrotic tissue, and to restore cardiac morphology by surgical repair and/or valve replacement. Cardiac operations in some of these critically ill patients may be challenging and yield poor early and late results, even when carefully performed. Mortality rates have been reported to range from 12% to 50%.

*From the Cardiovascular Department, University Hospital of Trieste, Italy (G.G., G.S., A. Pappalardo); Department of Thoracic and Cardiologic Surgery, EA3920 (A. Perrotti, S.C.) and Department of Infective and Tropical Diseases (C.C.), University Hospital Jean Minjoz, Besançon, France; Cardiology Hospital Louis Pradel, Hospices Civils, Lyon, France (J.-F.O., F.D.); IAME, Inserm UMR 1137, University Paris Diderot, Sorbonne Paris Cité, Paris, France (X.D.); Inserm Clinical Investigation Center 1425, Paris, France (X.D.); Department of Cardiology, AP-HP, Bichat Hospital, Paris, France (B.I.); DHU Fire, Paris, France (B.I.); EA 4003, University of Nancy, France (F.A.); Department of Cardiology, University Hospital of Nancy, France (C.S.-S.); Department of Infective and Tropical Diseases, University Hospital of Pointe à Pitre, France (B.H.); Department of Infective and Tropical Diseases, University Regional Hospital, Rennes, France (P.T., V.L.M.); UMI 233, Institute of Development Research, University of Montpellier, France (V.L.M.).

Accompanying Tables S1 through S4 are available at http://jaha.ahajournals.org/content/6/7/e004806/DC1/embed/inline-supplementary-material-1.pdf

*A complete list of the AEPEI Study Group members can be found in the Appendix at the end of the article.

**Correspondence to:** Giuseppe Gatti, MD, Cardiovascular Department, Ospedale di Cattinara, via Pietro Valdoni, 7, 34148 Trieste, Italy. E-mail: gius.gatti@gmail.com

Received October 5, 2016; accepted March 9, 2017.

© 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
The AEPEI Score  Gatti et al

between 10% in elective patients and up to 30% in urgent surgery. Prolonged invasive ventilation, low cardiac output, acute kidney injury, sepsis, and bleeding are frequent postoperative complications.1–3 Consequently, for patients with IE, risk stratification is important not only for the surgeon for decision making, but also for counseling of the patient and comparative assessment of quality of care.

Currently, the risk of mortality postsurgery for IE is estimated using predictive scoring systems that have been derived from patient databases where most of the patients had had cardiac operations other than those for endocarditis.4–7 Because of this inherent limitation, the utility of these aspecific predictive systems for patients with IE has been called into question.8–13 In fact, specific scores to predict in-hospital death postsurgery in patients with IE have also been devised,14–16 but with no external validation, and their impact in clinical practice is unclear.

In this context, we performed a prospective, population-based observational study in 8 European centers of cardiac surgery. The aims of the study were both to analyze the risk factors for hospital death and create a risk score based on the results of this analysis.

Methods

Study Patients

The study population consisted of 361 patients who underwent surgery for IE: (1) 138 consecutive patients (mean age, 60.6±8.5 years; 19.6% females) who were operated on between 2000 and 2015 at the Cardiovascular Department of the University Hospital of Trieste, Trieste, Italy; (2) 223 consecutive patients (mean age, 58.2±15.6 years; 22% females) who underwent surgery in 2008 in 7 French administrative areas: greater Paris, Lorraine, Rhône-Alpes, Franche-Comté, Marne, Ille-et-Vilaine, and Languedoc-Roussillon. The adult population in these areas (15.3 million inhabitants) covers 31.9% of the overall French population aged >18 years.11 The French centers are grouped in the Association for the study and prevention of IE (Association pour l’Étude et la Prévention de l’Endocardite Infectieuse; AEPEI). Since 2001, the members of the AEPEI (see Appendix for full list of members) are enrolling patients with IE in each of the French administrative areas in an ad-hoc prospective registry.17 In 2008, the data collection was particularly exhaustive, comprehensive, and accurate because it coincided with an epidemiological study performed by the AEPEI to update national data regarding the epidemiology of IE in France. Only definite cases of IE, as defined by the modified Duke criteria,18 were included into the present study. For all patients, baseline characteristics, surgical and endocarditis-related features, as well as postoperative complications were prospectively recorded in a computerized data registry. For each center, approval to conduct the study was acquired from the local ethics committee. Patients were informed about the study, but were not required to provide individual consent, in accord with French and Italian legislation.

A risk factor analysis for in-hospital death postsurgery for IE was performed and a predictive scoring system, named the AEPEI score, was devised from the results of the analysis. External validation was performed using data from the AEPEI registry of patients with definite IE who underwent surgery between 2001 and 2015. The validation sample comprised 161 AEPEI patients for whom there were sufficient data to calculate the AEPEI score. The 223 AEPEI patients operated on in 2008 and included in the present study had been excluded preventively from the validation sample.

Definitions

Unless otherwise stated, the definitions and cut-off values of the preoperative variables were those used for the European System for Cardiac Operative Risk Evaluation (EuroSCORE). In particular, critical state was defined as the presence of ventricular tachycardia/ventricular fibrillation or aborted sudden death, preoperative cardiac massage, preoperative ventilation before anesthetic room, preoperative inotropes or intra-aortic balloon pump, and preoperative acute renal failure (anuria or oliguria <10 mL/h).5,6 Myocardial infarction (MI) was defined according to the recent definition criteria of type V MI by Moussa et al.19 Acute kidney injury was defined as an increase in serum creatinine of 1.5 to 1.9 times the baseline level or serum creatinine increase ≥26.5 μmol/L within 7 days postsurgery.20 Sternal wound infections were graded according to the Centers for Disease Control and Prevention definitions of surgical site infections. In brief, superficial incisional infection involves only skin or subcutaneous tissues, deep incisional infection involves deep soft tissues (fascial and muscle layers) with or without the sternal bone, and organ/space infection involves the mediastinum (mediastinitis).21 For the purposes of this study, deep incisional infection and mediastinitis were considered to be deep sternal wound infections. Any sternal wound infection occurring within 3 months postsurgery was considered as postoperative wound infection.

Statistical Analysis

Continuous variables with normal distribution are expressed as mean±SD and those without normal distribution as median [interquartile range]. Categorical variables are expressed as number and percentage. Statistical comparison of baseline characteristics was performed using Pearson’s chi-square or Fisher’s exact test for categorical variables, and Student t test.

DOI: 10.1161/JAHA.116.004806

Journal of the American Heart Association
or the Mann–Whitney U test for continuous variables. Backward step-wise multivariable logistic regression analysis was used to identify independent predictors of in-hospital mortality. All variables with a P<0.1 by univariable analysis were included in the multivariable model. For each variable, the odds ratio (OR) and the corresponding 95% CI were calculated. Each of the risk indices had the variable weighted according to its regression coefficient. Goodness of fit of the model was evaluated with the Hosmer–Lemeshow test. The discriminatory power of the model was assessed with the receiver operating characteristic (ROC) curve and the calculation of the area under the curve (AUC). The new predictive scoring system, the AEPEI score, was compared (using De Long’s method) with 3 existing scoring systems for in-hospital mortality after cardiac surgery, namely the EuroSCORE II,5 the logistic EuroSCORE,16 and the Ontario Province Risk (OPR) score,17 as well as with 3 existing scores specifically designed to predict early mortality postsurgery for IE, namely the PALSUSE score (the prosthetic valve, age ≥70, large model was evaluated with the Hosmer–Lemeshow test. The discriminatory power of the model was assessed with the receiver operating characteristic (ROC) curve and the calculation of the area under the curve (AUC). The new predictive scoring system, the AEPEI score, was compared (using De Long’s method) with 3 existing scoring systems for in-hospital mortality after cardiac surgery, namely the EuroSCORE II,5 the logistic EuroSCORE,16 and the Ontario Province Risk (OPR) score,17 as well as with 3 existing scores specifically designed to predict early mortality postsurgery for IE, namely the PALSUSE score (the prosthetic valve, age ≥70, large

Table 1. Baseline Characteristics of Patients (n=361)*

| Variable | Trieste Database (n=138) | AEPEI Registry (n=223) | P Value |
|----------|-------------------------|------------------------|---------|
| Age, y   | 60.6±8.5                | 58.2±15.6              | 0.15    |
| Female sex | 27 (19.6)              | 49 (22.0)              | 0.58    |
| Hypertension | 21 (15.2)             | 90 (40.4)              | <0.0001 |
| Current smoker | 11 (8)                | 54 (24.2)              | <0.0001 |
| BMI, kg/m² | 25.5±4.1              | 25.4±5.4               | 0.88    |
| Diabetes mellitus | 22 (15.9)       | 48 (21.5)              | 0.19    |
| Diabetes mellitus on insulin | 9 (6.5)       | 18 (8.1)               | 0.58    |
| Anemia⁷  | 113 (81.9)              | 171 (76.6)             | 0.95    |
| White blood cell, 10⁹/mm³ | 12±5.9              | 14.9±10.5              | 0.0032  |
| CRP, mg/L | 193.6±81.3            | 140.4±85.5             | <0.0001 |
| Poor mobility¹ | 2 (1.4)             | 18 (8.1)               | 0.0075  |
| Chronic lung disease² | 13 (9.4)           | 20 (9.0)               | 0.88    |
| eGFR, ml/min⁶ | 67.7±37.3            | 69.4±35.4              | 0.67    |
| Dialysis | 13 (9.4)                | 2 (0.9)                | <0.0001 |
| Extracardiac arteriopathy³ | 22 (15.9)          | 28 (12.6)              | 0.36    |
| NYHA class IV | 55 (39.9)          | 81 (36.3)              | 0.5     |
| CCS class 4 | 20 (14.5)            | 3 (1.3)                | <0.0001 |
| Recent MI⁴ | 0                      | 1 (0.4)                | 1       |
| Left ventricular ejection fraction <50%¹ | 32 (23.2)       | 43 (19.3)              | 0.37    |
| sPAP >55 mm Hg † | 3 (2.2)           | 15 (12.4)              | 0.053   |
| Coronary artery disease | 18 (13)               | 25 (18.1)              | 0.6     |
| Previous cardiac surgery | 37 (26.8)           | 17 (7.6)               | <0.0001 |
| Critical state ‡ | 27 (19.6)             | 35 (15.7)              | 0.34    |
| Length of the preoperative hospital stay (days)⁴ | 6 [2–19]         | 13 [5–25]              | 0.16    |

CABG indicates coronary artery bypass grafting; EuroSCORE, European System for Cardiac Operative Risk Evaluation. *Number (percentage). **Perivalvular leak, annular or aortic abscess, sinus of Valsalva aneurysm, aortic fistula, and prosthetic valve detachment. §The definitions are those used for the EuroSCORE II. Thedefinitions are those used for the EuroSCORE II. "Defined as extensive valve destruction, perivalvular complications, or multivalvular involvement.

Table 2. Surgical Features (n=361)*

| Variable | Trieste Database (n=138) | AEPEI Registry (n=223) | P Value |
|----------|-------------------------|------------------------|---------|
| Reason for surgery |                      |                        |         |
| Refractory heart failure attributed to valvular dysfunction | 32 (23.2)             | 59 (26.5)             | 0.49    |
| Persistent infection | 18 (13)               | 28 (12.6)              | 0.89    |
| Embolism | 58 (42)                 | 106 (47.5)             | 0.31    |
| Recurrent | 4 (2.9)                | 49 (22)                | <0.0001 |
| Perivalvular complications † | 40 (29)             | 67 (30)                | 0.82    |
| Surgical priority ‡ |                      |                        | <0.0001 |
| Elective | 26 (18.8)               | 107 (48.0)             |         |
| Urgent | 90 (65.2)               | 94 (42.2)              |         |
| Emergency | 22 (15.9)             | 11 (4.9)               |         |
| Salvage | 0                      | 11 (4.9)               |         |
| Valve involvement |                      |                        |         |
| Aortic valve | 86 (62.3)             | 138 (61.9)             | 0.93    |
| Mitral valve | 60 (43.5)             | 107 (48.0)             | 0.40    |
| Tricuspid valve | 7 (5.1)              | 28 (12.6)              | 0.02    |
| Multivalvular | 23 (16.7)             | 55 (24.7)              | 0.07    |
| Large intracardiac destruction ‡ | 57 (41.3)           | 119 (52)               | 0.08    |
| Weight of the intervention † |                      |                        |         |
| Combined CABG | 25 (18.1)             | 13 (5.8)               | <0.0001 |
| Single non-CABG | 89 (64.5)             | 126 (56.5)             | 0.13    |
| Two procedures | 46 (33.3)             | 82 (36.8)              | 0.51    |
| Three procedures | 3 (2.2)              | 15 (6.7)               | 0.053   |
| Surgery on thoracic aorta | 9 (6.5)               | 15 (6.7)               | 0.94    |

CABG indicates coronary artery bypass grafting; EuroSCORE, European System for Cardiac Operative Risk Evaluation. *Number (percentage). **Perivalvular leak, annular or aortic abscess, sinus of Valsalva aneurysm, aortic fistula, and prosthetic valve detachment. §The definitions are those used for the EuroSCORE II. Thedefinitions are those used for the EuroSCORE II. "Defined as extensive valve destruction, perivalvular complications, or multivalvular involvement.

CS indicates Canadian Cardiovascular Society; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; EuroSCORE, European System for Cardiac Operative Risk Evaluation; MI, myocardial infarction; NYHA, New York Heart Association; ROC, receiver operating characteristic; sPAP, systolic pulmonary artery pressure.

*Unless otherwise stated, values are mean±SD, or number (percentage).

†Defined as haemoglobin <12 g/dL for women and <13 g/dL for men.

‡The definitions and the cut-off values are those used for the EuroSCORE II.5

§The creatinine clearance rate, calculated according to the Cockcroft-Gault formula, was used to estimate GFR.

†Median [interquartile range].
intracardiac destruction, *Staphylococcus* spp, urgent surgery, sex [female], and EuroSCORE $\geq 10$, the De Feo score (for native valve IE), and the Society of Thoracic Surgeons (STS) score for IE. Both internal validation, based on the 0.632 bootstrap method, and external validation were performed. In addition, a new set of statistical analyses was carried out as follows: (1) In order to verify the stability of the original 5-variable model of the AEPEI score without the variable linked to pulmonary artery pressure, an alternate model of the AEPEI score was created by removing systolic pulmonary artery pressure (sPAP) $> 55$ mm Hg from the original set of variables from which the score was generated. The goodness of fit and the discriminatory power of this alternate model were measured. (2) Because all the variables of the AEPEI score except BMI $> 27$ kg/m² were also components of the EuroSCORE II, we added BMI $> 27$ kg/m² to EuroSCORE II and investigated its incremental value with continuous net reclassification improvement and integrated discrimination improvement measures. (3) Given the ratio of events to potential predictor variables, Akaike’s information criterion (AIC), which accounts for the small number of events relative to the number of covariates, was analyzed.

Statistical analyses were performed using SPSS for Windows (version 13.0; SPSS, Inc, Chicago, IL).

**Table 3. Endocarditis-Related Features (n=361)**

| Variable | Trieste Database (n=138) | AEPEI Registry (n=223) | P Value |
|----------|--------------------------|------------------------|---------|
| Endocarditis | | | $<0.0001$ |
| Active† | 72 (52.2) | 203 (91) | |
| Treated† | 66 (47.8) | 20 (9.0) | |
| Type of endocarditis | | | |
| Native valve | 103 (74.6) | 182 (81.6) | 0.78 |
| Prosthetic valve | 27 (19.6) | 41 (18.3) | 0.78 |
| Intracardiac device or other side | 12 (8.7) | 36 (16.1) | 0.043 |
| Causal agents | | | 0.014 |
| *Streptococcus* species | 45 (32.6) | 89 (39.9) | |
| *Staphylococcus aureus* | 23 (16.7) | 49 (22) | |
| Coagulase-negative *Staphylococci* | 10 (7.2) | 23 (10.3) | |
| *Enterococcus* species | 13 (9.4) | 24 (10.8) | |
| Gram-negative bacteria | 6 (4.3) | 9 (4) | |
| Fungi | 2 (1.4) | 2 (0.9) | |
| Not identified | 39 (28.3) | 27 (12.1) | |

EuroSCORE indicates European System for Cardiac Operative Risk Evaluation. *Number (percentage).†The definitions are those used for the EuroSCORE II.

**Table 4. In-Hospital Mortality and Perioperative Complications**

| Complication | n=361 |
|--------------|-------|
| In-hospital death | 56 (15.5) |
| 30-day death | 42 (11.6) |
| Stroke | 9 (2.5) |
| Prolonged (>48 hours) invasive ventilation | 482 (22.7) |
| Pneumonia | 30 (8.3) |
| Atrial fibrillation, new onset | 38/358† (10.6) |
| MI$^{18}$ | 2 (0.6) |
| Immediate reoperation for acute prosthetic failure | 9 (2.5) |
| Low cardiac output$^{1}$ | 32 (8.9) |
| Intraoperative and postoperative use of IABP | 9 (2.5) |
| Use of ECMO | 6 (1.7) |
| Acute kidney injury$^{20}$ | 67 (18.6) |
| Renal replacement therapy | 23 (6.4) |
| Bleeding peptic disease | 4 (1.1) |
| Mesenteric ischemia | 7 (1.9) |
| Acute pancreatitis | 2 (0.6) |
| Multigorgan failure (3 or more organs) | 11 (3.0) |
| Sepsis | 22 (6.1) |
| Mediastinal re-exploration$^{3}$ | 38 (10.5) |
| Deep sternal wound infection$^{21}$ | 10 (2.8) |
| Length of the postoperative hospital stay, days | 23.9 [12.7–42.4]$^{21}$ |

ECMO indicates extracorporeal membrane oxygenator; IABP, intra-aortic balloon pumping; KDIGO, Kidney Disease: Improving Global Outcomes; MI, myocardial infarction. *Unless otherwise stated, values are number (percentage).†Patients with preoperative stable sinus rhythm or paroxysmal atrial fibrillation.‡Defined as 3 consecutive cardiac index measurements $<2.0$ L/min per m² despite adequate preload, afterload and inotropic support, or IABP.$^{3}$Through resternotomy or subxifoid window.$^{21}$Median [interquartile range].

**Results**

**Italian Versus French Study Patients**

There were some differences in baseline characteristics, surgical data, and endocarditis-related features between the Italian and French patients of the study. The rates of preoperative dialysis, Canadian Cardiovascular Society (CCS) class 4, previous cardiac surgery, urgent/emergency priority, and combined coronary surgery were higher in Italian patients, whereas poor mobility, recurrent embolism, and active endocarditis were more frequent in French patients. Baseline levels of C-reactive protein were higher in Italian patients.
patients (Tables 1 through 3). Overall, the expected operative risk was higher in Italian patients than in the French series (mean EuroSCORE II, 15.9±18.7% versus 9.9±3.6%; \( P<0.001 \)). In-hospital mortality was higher in Italian than in French patients (20.3% versus 12.6%; \( P=0.049 \)); 30-day mortality was also higher in the Italian series (18.1% versus 7.6%; \( P=0.0025 \)).

Risk Factors for Hospital Death and Multivariable Analysis Model

A total of 56 (15.5%) patients died in hospital after surgery (Table 4). Baseline characteristics and operative data of these patients and the corresponding endocarditis-related features (Table S1) were compared with those of survivors of the in-hospital phase postsurgery (Tables S2 through S4). Risk factor analysis for in-hospital death postsurgery for IE was performed. A multivariable model with 16 variables was created using all the variables with a \( P<0.1 \) by univariable analysis. BMI >27 kg/m\(^2\), estimated glomerular filtration rate (eGFR) <50 mL/min, New York Heart Association (NYHA) class IV, sPAP >55 mm Hg, and critical state were found to be independent predictors of postoperative in-hospital death (Tables 5 and 6).

The AEPEI Score: Performance and Validation

By multivariable analysis (Table 5), a new scoring system, the AEPEI score, was created to predict in-hospital mortality postsurgery for IE (Table 6). The new score includes 5 variables and consists of 7 risk classes (Table 7); its performance is summarized in Tables 8 and 9. In the study population, the AEPEI score had equivalent discriminatory power to that of the EuroSCORE II (\( P=0.4 \)). It was found to be better than the logistic EuroSCORE (\( P=0.0026 \)) and OPR score (\( P=0.065 \)) and better than each of the 3 specific predictive systems (De Feo score, \( P=0.054 \), PALSUSE score, \( P=0.047 \), and STS risk score for IE; \( P=0.027 \)), albeit without reaching statistical significance for the De Feo score (Figure 1). There was no difference in performance of the AEPEI score between patients with and without IE.

### Table 5. Risk Factor Analysis for In-Hospital Death After Surgery for IE (n=361)

| Variable | Univariable Analysis* | Original Multivariable Analysis† | Alternate Multivariable Analysis‡ |
|----------|------------------------|----------------------------------|----------------------------------|
|          | \( P \) Value | OR | 95% CI | \( P \) Value | OR | 95% CI | \( P \) Value | OR | 95% CI |
| Age >70 years | 0.016 | 1.14 | 0.52 to 2.53 | 0.74 | 1.18 | 0.55 to 2.55 | 0.67 |
| BMI >27 kg/m\(^2\) | 0.039 | 2.15 | 1.06 to 4.37 | 0.034 | 1.91 | 0.96 to 3.81 | 0.065 |
| eGFR <50 mL/min\(^*\) | <0.0001 | 3.62 | 1.78 to 7.78 | <0.0001 | 3.19 | 1.59 to 6.41 | <0.0001 |
| Dialysis | 0.066 | 1.04 | 0.27 to 3.96 | 0.96 | 1.47 | 0.41 to 5.27 | 0.56 |
| NYHA class IV | 0.0001 | 2.43 | 1.14 to 5.18 | 0.022 | 2.07 | 1.00 to 4.27 | 0.05 |
| CCS class 4 | 0.015 | 1.13 | 0.38 to 3.3 | 0.83 | 1.19 | 0.41 to 3.45 | 0.74 |
| Left ventricular ejection fraction, 30% to 50%\(^*\) | 0.036 | 1.37 | 0.65 to 2.9 | 0.41 | 1.29 | 0.61 to 2.72 | 0.51 |
| sPAP >55 mm Hg\(^*\) | 0.044 | 3.29 | 1.13 to 9.53 | 0.028 | ... | ... | ... |
| Coronary artery disease | 0.052 | 1.33 | 0.1 to 17.9 | 0.83 | 1.46 | 0.11 to 18.6 | 0.77 |
| Previous cardiac surgery | 0.022 | 1.29 | 0.48 to 3.48 | 0.61 | 1.30 | 0.50 to 3.38 | 0.59 |
| Critical state\(^*\) | <0.0001 | 2.52 | 1.11 to 5.73 | 0.027 | 2.49 | 1.11 to 5.78 | 0.026 |
| Length of the preoperative hospital stay <10 days\(^*\) | 0.061 | 1.12 | 0.52 to 2.44 | 0.77 | 1.06 | 0.51 to 3.39 | 0.87 |
| Urgent surgical priority\(^*\) | 0.006 | 1.62 | 0.76 to 3.47 | 0.21 | 1.80 | 0.84 to 3.83 | 0.13 |
| Combined CABG | 0.052 | 1.49 | 0.12 to 2.34 | 0.77 | 1.26 | 0.09 to 17.8 | 0.87 |
| Surgery on thoracic aorta | 0.075 | 2.44 | 0.69 to 8.67 | 0.17 | 2.55 | 0.78 to 8.31 | 0.12 |
| Prosthetic valve endocarditis | 0.043 | 1.49 | 0.61 to 6.34 | 0.38 | 1.45 | 0.61 to 3.45 | 0.4 |

CABG indicates coronary artery bypass grafting; CCS, Canadian Cardiovascular Society; eGFR, estimated glomerular filtration rate; EuroSCORE, European System for Cardiac Operative Risk Evaluation; NYHA, New York Heart Association; OR, odds ratio; ROC, receiver operating characteristic curve; sPAP, systolic pulmonary artery pressure.

*All the variables that were considered for the univariable analysis are listed in Table S1.

†All variables with a \( P<0.1 \) by univariable analysis were included in the multivariable model.

‡All variables with a \( P<0.1 \) by univariable analysis except sPAP >55 mm Hg were included in the multivariable model.

§The best discriminative value for in-hospital mortality by ROC analysis.

¶The creatinine clearance rate, calculated according to the Cockcroft-Gault formula, was used to estimate GFR.

\(^*\) The definitions and cut-off values are those used for EuroSCORE II.
Table 6. The AEPEI Score: the Risk Factors for In-Hospital Death (by Backward Multivariable Logistic Regression) and the Scoring (n=361)

| Variable | The Original Model* | The Alternate Model† |
|----------|---------------------|----------------------|
|          | Regression Coefficient | SE | OR | 95% CI | P Value | Points | Regression Coefficient | SE | OR | 95% CI | P Value | Points |
| BMI >27 kg/m² | 0.58 | 0.34 | 1.79 | 1.02 to 3.45 | 0.049 | 1 | ... | ... | ... | ... | ... | ... |
| eGFR <50 mL/ min⁻¹⁻¹ | 1.26 | 0.33 | 3.52 | 1.84 to 6.73 | <0.0001 | 2.2 | 1.32 | 0.33 | 3.75 | 1.97 to 7.14 | <0.0001 | 1.8 |
| NYHA class IV | 0.75 | 0.33 | 2.11 | 1.10 to 4.05 | 0.024 | 1.3 | 0.75 | 0.33 | 2.12 | 1.12 to 4.02 | 0.021 | 1 |
| sPAP >55 mm Hg* | 0.58 | 0.58 | 1.78 | 1.06 to 5.61 | 0.032 | 1 | ... | ... | ... | ... | ... |
| Critical state‡ | 0.86 | 0.36 | 2.37 | 1.16 to 4.82 | 0.017 | 1.5 | 0.85 | 0.36 | 2.35 | 1.17 to 4.74 | 0.017 | 1.1 |
| Constant | −3.065 | | | | | | | −1.411 | | | |

The 3 variables of the alternate model of the AEPEI score remained significant by bootstrap internal validation (Table 11). By external validation, there were no significant differences between expected and observed deaths ($\chi^2=2.7; 5 df, P=0.75$; Table 12) and the discriminatory power of the score was confirmed to be good (AUC, 0.715; 95% CI, 0.638–0.783; Figure 2).

The Alternative 3-Variable AEPEI Score Model

According to the alternate multivariable model (Table 5), an alternate model of the AEPEI score was created (Table 6). This model includes 3 variables and consists of 4 risk classes (Table 7). Its discriminatory power was equivalent to that of the original 5-variable model ($P=0.49$); calibration was slightly lower (Tables 8 and 13; Figure 3). There was no significant difference in the performance of the alternate model of the AEPEI score between the Italian and the French series ($P=0.29$; Table 10). The logistic equation of the alternate AEPEI model was:

$$p = \frac{e^{(\beta_0 + \sum \beta_i X_i)}}{1 + e^{(\beta_0 + \sum \beta_i X_i)}}$$

where $\beta_0$ is the constant of the logistic regression equation (ie, $-3.0645$) and $\beta_i$ the coefficient of the variable $X_i$. The coefficients and variable values are: for BMI, $\beta_i=0.58$ and $X_i=1$ if BMI $>27$ kg/m², or 0 if BMI $\leq 27$ kg/m²; for eGFR, $\beta_i=1.26$ and $X_i=1$ if eGFR $<50$ mL/min, or 0 if eGFR $\geq 50$ mL/min; and for NYHA class IV, $\beta_i=0.75$ and $X_i=1$ if NYHA class IV 0 if not; for sPAP, $\beta_i=0.58$ and $X_i=1$ if sPAP $>55$ mm Hg, or 0 if sPAP $\leq 55$ mm Hg; for critical state, $\beta_i=0.86$ and $X_i=1$ if the patient is in critical state, or 0 if not (Table 6).

The AEPEI Incrimented EuroSCORE II

The variable BMI $>27$ kg/m² was added to the EuroSCORE II. The integrated discrimination improvement was 0.027.
| Scoring System | Study Population | Variables (Points) | Discrimination Power | Expected Hospital Mortality |
|----------------|------------------|--------------------|----------------------|-----------------------------|
| **AEPEI score, the original model**<sup>*</sup> (2016) | 361 pts. (mean age, 59.1±15.4 years); AEPEI registry (223 pts., 7 French hospitals, 2008) & Cardiovascular Department of Trieste, Italy (138 pts., 2000–2015); Hospital mortality, 15.5%; 30-Day mortality, 11.6% | 5 variables: BMI >27 kg/m² (1) eGFR <50 mL/min (2.2) NYHA class IV (1.3) sPAP >55 mm Hg (1) Critical state (1.5) | AUC, 0.780 (95% CI, 0.734–0.822) | Score, 0 to 1 point: expected mortality, 4.5% to 7.7%; Score, 1.3 to 2 points: expected mortality, 9% to 12.9%; Score, 2.2 to 2.8 points: expected mortality, 14.1% to 18.9%; Score, 3.2 to 3.8 points: expected mortality, 22.6% to 29.4%; Score, 4.5 to 5 points: expected mortality, 38.2% to 45.1%; Score, 5.5 to 6 points: expected mortality, 52.5% to 59.4%; Score, 7 points: expected mortality, 72.4% |
| **AEPEI score, the alternate model**<sup>*</sup> (2016) | Idem | 3 variables: eGFR <50 mL/min (1.8) NYHA class IV (1) Critical state (1.1) | AUC, 0.774 (95% CI, 0.727–0.816) | Score, 0 to 1 point: expected mortality, 19.6% to 34.1%; Score, 1.1 to 1.8 points: expected mortality, 36.6% to 47.7%; Score, 2.1 to 2.9 points: expected mortality, 55% to 68.3%; Score, 3.9 points: expected mortality, 82% |
| **PALSUSE score**<sup>14</sup> (2014) | 437 pts. (mean age, 61.4±15.5 years); GAMES registry (26 Spanish hospitals, 2008–2010); Hospital mortality, 24.3% | 7 variables: Prosthetic valve (2) Age ≥70 years (1) Large intracardiac destruction (2) Staphylococcus spp (2) Urgent surgery (2) Sex, female (2) EuroSCORE II ≥10% (1) | AUC, 0.84 (95% CI, 0.79–0.88) | Hospital mortality ranged from 0, in patients with score = 0, to 45.4% in patients with score >3 |
| **De Feo score**<sup>15</sup> (2012) for native valve IE | 440 pts. (mean age, 49±16 years); Department of Cardiothoracic Surgery of Naples, Italy (1980–2009); Hospital mortality, 9.1% | 6 variables: Age, 5 classes (5–13) Renal failure (5) NYHA class IV (9) Preop. ventilator support (11) Positivity of latest preop. blood cultures (5) Perivalvular involvement (5) | AUC, 0.88 (95% CI, 0.82–0.93) | Score, 0 to 5 points: expected mortality ≤4.55%; Score, 7 to 13 points: expected mortality, 4.55% to 9.1%; Score, 14 to 19 points: expected mortality, 9.2% to 27.3%; Score ≥20 points: expected mortality >27.3% |
| **STS risk score for IE**<sup>16</sup> (2011) | 19 543 pts. (mean age, 55 years); STS database (2002–2008); 30-day mortality, 8.2% | 12 variables: Emergency, salvage status, or cardiogenic shock (17) Preop. hemodialysis, renal failure, or creatinine level >2.0 mg/dL (12) Preop. inotropic or balloon pump support (10) Active (vs treated) endocarditis (10) Multiple valve involvement (9) Insulin-dependent diabetes mellitus (8) Arrhythmia (8) Previous cardiac surgery (7) Urgent status without cardiogenic shock (6) Non-insulin-dependent diabetes mellitus (6) Hypertension (5) Chronic lung disease (5) | AUC, 0.758 | … |

AEPEI indicates Association pour l’Étude et la Prévention de l’Endocardite Infectieuse; AUC, area under the receiver operating characteristic (ROC) curve; eGFR, estimated glomerular filtration rate; EuroSCORE, European System for Cardiac Operative Risk Evaluation; GAMES, Grupo de Apoyo al Manejo de la Endocarditis Infectiosa en España; IE, infective endocarditis; NYHA, New York Heart Association; PALSUSE, Prosthetic valve, Age ≥70, Large intracardiac destruction, Staphylococcus spp, Urgent surgery, Sex [female], EuroSCORE II ≥10%; Preop., preoperative; pts., patients; sPAP, systolic pulmonary artery pressure; STS, the Society of Thoracic Surgery.

*Table 6.
The continuous net reclassification improvement was 0.13 \( (P=0.37) \). The AIC Analysis

With 56 events and 16 variables in the initial logistic regression (with multiple categories that further increase the dimension), the initial model was severely overfit (Table 5). However, according to the AIC,22 each predictive system that was considered in this study except EuroSCORE II was \(<0.0001\) times as probable as the AEPEI score to minimize the information loss. The alternate AEPEI model was \(0.0091\) times as probable as the original AEPEI model to minimize the information loss (Table 8).

Discussion

Based on analysis of perioperative data from 361 patients from 8 European centers of cardiac surgery, we devised a weighted scoring system to predict in-hospital mortality postsurgery for IE, namely the AEPEI score. The score is composed of only 5 variables and consists of 7 classes of risk. It was derived from a backward step-wise logistic regression model that was created to find the independent predictors of in-hospital death in this series of patients with IE. Although the variables of the model were chosen from a pool of baseline characteristics of the patients, surgical data, and endocarditis-related features, all the variables of the AEPEI score (BMI \( \geq \) 27 kg/m\(^2\), eGFR < 50 mL/min, NYHA class IV, sPAP > 55 mm Hg, and critical state) refer to the patient’s preoperative state and include an anthropometric measurement, a laboratory finding, an estimate of resting dyspnea, an invasive (or ultrasound) intracardiac pressure measurement, and a well-defined composite variable of events indicating the critical preoperative state of the patient.

The goodness of fit of the statistical model was satisfactory and the score showed a good discriminatory power. Both internal and external validation of the AEPEI score were performed. The results of the validation procedures confirmed satisfactory calibration and discriminatory power of the score. In the study population, the AEPEI score performed better than 3 specific scoring systems for in-hospital (or 30-day) mortality postsurgery for IE that were considered18–20 and was superior to 214,16 of the 3 scoring systems for in-hospital (or 30-day) mortality after any cardiac operation that were used for comparison. These results were confirmed also according to a more-robust approach such as the AIC.22 In addition, the AEPEI score is not intended only for native valve endocarditis, as is the De Feo score,15 and the AEPEI score includes a composite variable, that is, critical state, similar to what applies in the PALSUSE and STS risk scores for IE.18,20 The AEPEI score was found to be equivalent to EuroSCORE II, which consists of 18 (simple and composite) variables and was modeled from a contemporary surgical cohort of 22 381 patients, including 497 (2.2%) with active IE.5

### Table 8. Performance of the AEPEI Score (2 Models) and of 6 Other Specific/Nonspecific Predictive Scoring Systems for In-Hospital Mortality After Surgery for IE in the Original Series of Patients

| System                          | Original Series (n=361) | Goodness of Fit* | Discriminatory Power† | AIC Value\(^{23}\) |
|---------------------------------|-------------------------|------------------|-----------------------|-------------------|
|                                 |                         | Chi-square | DF | \( P \) Value | AUC | 95% CI |                   |
| Specific                        |                         |            |    |              |     |        |                   |
| AEPEI score, the original model |                         | 2.6        | 5  | 0.76        | 0.780| 0.734 to 0.822| 257.5             |
| AEPEI score, the alternate model|                         | 3.9        | 3  | 0.27        | 0.774| 0.727 to 0.816| 266.9             |
| PALSUSE score\(^{14}\)          |                         | 2.3        | 7  | 0.97        | 0.684| 0.633 to 0.731| 289.1             |
| De Feo score for native valve IE\(^{15}\) | | 2.8        | 6  | 0.9       | 0.722| 0.654 to 0.790| 296.8             |
| STS risk score for IE\(^{16}\)  |                         | 7.9        | 8  | 0.44        | 0.709| 0.659 to 0.756| 300               |
| Aspecific                       |                         |            |    |              |     |        |                   |
| EuroSCORE II\(^{5}\)           |                         | 9.5        | 8  | 0.3         | 0.751| 0.704 to 0.795| 132.5             |
| Logistic EuroSCORE\(^{6}\)     |                         | 14.3       | 8  | 0.068       | 0.632| 0.580 to 0.682| 306.9             |
| OPR score\(^{7}\)              |                         | 12.1       | 8  | 0.15        | 0.698| 0.647 to 0.745| 288.7             |

AEPEI indicates Association pour l’Etude et la Prévention de l’Endocardite Infectieuse; AIC, Akaike’s information criterion; AUC, area under the receiver operating characteristic (ROC) curve; DF, degrees of freedom; EuroSCORE, European System for Cardiac Operative Risk Evaluation; IE, infective endocarditis; NYHA, New York Heart Association; OPR, Ontario Province Risk; PALSUSE, prosthetic valve, age \( \geq 70\), large intracardiac destruction, Staphylococcus spp, urgent surgery, sex (female), EuroSCORE II \( \geq 10\%\); STS, the Society of Thoracic Surgeons.

* By the Hosmer–Lemeshow test for logistic regression.
† By ROC analysis.

DOI: 10.1161/JAHA.116.004806

Journal of the American Heart Association

8
undergoing surgery for IE has been evaluated by other investigators. Some researchers think that it underestimates post-cardiac surgery mortality in these patients; others have demonstrated poor calibration and comparatively poor discrimination of the system for emergency cardiac surgery. Yet, others believe that the EuroSCORE II may be a useful and appropriate tool for estimating perioperative risk, even for IE patients, and that specific endocarditis features will increase model complexity without an unequivocal improvement in predictive ability. Consequently, there is a lack of consensus on this issue. To improve the EuroSCORE II performance in IE, we added the only variable present in the AEPEI score that is not in the EuroSCORE II (namely, BMI > 27 kg/m²).

Figure 1. The new predictive scoring system for in-hospital death postsurgery for IE (the AEPEI score) vs (A) three scoring systems specifically created to predict in-hospital (or 30-day) mortality postsurgery for IE and (B) 3 predictive scoring systems for in-hospital (or 30-day) mortality after cardiac surgery. AEPEI indicates Association pour l’Etude et la Prévention de l’Endocadiite Infectieuse; AUC, area under the receiver operating characteristic curve; EuroSCORE, European System for Cardiac Operative Risk Evaluation; IE, infective endocarditis; OPR, Ontario Province Risk; PALSUSE, Prosthetic valve, Age ≥70, Large intracardiac destruction, Staphylococcus spp, Urgent surgery, Sex [female], EuroSCORE ≥10; STS, the Society of Thoracic Surgeons.

Table 9. The AEPEI Score, the Original Model: Contingency Table for the Hosmer–Lemeshow Test for Logistic Regression (n=361)

| Group | Death | Survival |
|-------|-------|----------|
|       | Observed | Expected | Observed | Expected | Total |
| 1     | 4 | 5.2 | 113 | 111.8 | 117 |
| 2     | 2 | 3.2 | 39 | 37.8 | 41 |
| 3     | 5 | 4.5 | 45 | 45.5 | 50 |
| 4     | 7 | 4.5 | 26 | 28.5 | 33 |
| 5     | 7 | 8.0 | 33 | 32.0 | 40 |
| 6     | 11 | 10.2 | 26 | 26.8 | 37 |
| 7     | 20 | 20.4 | 23 | 22.6 | 43 |

AEPEI indicates Association pour l’Etude et la Prévention de l’Endocadiite Infectieuse.
critical state) that had equivalent discriminatory power, but lower goodness of fit, compared to the original AEPEI score. Unlike other predictive systems, no infectious agent was related to an increased in-hospital mortality postsurgery. However, in the present experience, there was an under-representation of potentially catastrophic organisms, such as

| Table 10. Performance of the Considered Predictive Scores in the Trieste Database and in the AEPEI Registry |
| --- |
| **System** | **Trieste Database (n=138)** | **AEPEI Registry (n=223)** |
|  | Goodness of Fit* | Discriminatory Power† | Goodness of Fit* | Discriminatory Power† |
|  | Chi-square | DF | P Value | AUC | 95% CI | Chi-square | DF | P Value | AUC | 95% CI |
| Specific | AEPEI score, the original model | 12.6 | 6 | 0.55 | 0.744 | 0.662 to 0.814 | 4.5 | 5 | 0.49 | 0.804 | 0.746 to 0.854 |
|  | AEPEI score, the alternate model | 5.03 | 4 | 0.28 | 0.732 | 0.650 to 0.804 | 1.5 | 3 | 0.68 | 0.802 | 0.744 to 0.852 |
|  | PALSUSE score† | 3.4 | 7 | 0.85 | 0.723 | 0.640 to 0.795 | 6.3 | 7 | 0.5 | 0.691 | 0.626 to 0.751 |
|  | De Feo score (for native valve IE) | 1.6 | 6 | 0.95 | 0.730 | 0.648 to 0.802 | 5.2 | 6 | 0.63 | 0.720 | 0.656 to 0.778 |
|  | STS risk score for IE | 3.3 | 8 | 0.92 | 0.706 | 0.623 to 0.780 | 3.1 | 8 | 0.93 | 0.740 | 0.677 to 0.796 |
| Aspecific | EuroSCORE II | 4.2 | 8 | 0.84 | 0.763 | 0.683 to 0.831 | 5.1 | 8 | 0.65 | 0.772 | 0.711 to 0.825 |
|  | Logistic EuroSCORE | 15.5 | 8 | 0.05 | 0.658 | 0.572 to 0.736 | 13.8 | 8 | 0.088 | 0.500 | 0.433 to 0.568 |
|  | OPR score | 13.8 | 8 | 0.087 | 0.637 | 0.551 to 0.717 | 3.9 | 8 | 0.87 | 0.694 | 0.656 to 0.753 |

AEPEI indicates Association pour l’Etude et la Prévention de l’Endocardite Infectieuse; AUC, area under the receiver operating characteristic (ROC) curve; DF, degrees of freedom; EuroSCORE, European System for Cardiac Operative Risk Evaluation; IE, infective endocarditis; NYHA, New York Heart Association; OPR, Ontario Province Risk; PALSUSE, prosthetic valve, age ≥70, large intracardiac destruction, Staphylococcus spp, urgent surgery, sex (female), EuroSCORE II ≥10%; STS, The Society of Thoracic Surgeons.

*By the Hosmer–Lemeshow test for logistic regression.
†By ROC analysis.

Table 11. Bootstrap Analysis of the Logistic Regression Model From Which the Original Model of the AEPEI Score was Generated*

| Variable | A | Bias | SE | 95% CI | P Value |
| --- | --- | --- | --- | --- | --- |
| Age >70 years | 0.40 | –0.01 | 0.40 | –0.41 to 1.15 | 0.27 |
| BMI >27 kg/m² | 0.72 | 0.03 | 0.38 | –0.02 to 1.43 | 0.03 |
| eGFR <50 mL/min | 1.11 | 0.09 | 0.39 | 0.43 to 1.99 | 0.01 |
| Dialysis | 0.19 | –0.13 | 2.03 | –2.09 to 2.06 | 0.83 |
| NYHA class IV | 0.81 | 0.03 | 0.43 | 0.03 to 1.76 | 0.028 |
| CCS class 4 | 0.27 | –0.02 | 0.67 | –1.22 to 1.54 | 0.63 |
| Left ventricular ejection fraction, 30% to 50% | 0.26 | 0.01 | 0.41 | –0.51 to 1.06 | 0.48 |
| sPAP >55 mm Hg | –1.24 | –0.21 | 1.10 | –2.77 to –0.36 | 0.013 |
| Coronary artery disease | 0.33 | 5.57 | 9.88 | –20.8 to 3.25 | 0.502 |
| Previous cardiac surgery | 0.41 | 0.01 | 0.52 | –0.60 to 1.41 | 0.41 |
| Critical state | 0.97 | 0.06 | 0.51 | –0.01 to 2.08 | 0.042 |
| Length of the preop. hospital stay <10 days | 0.16 | –0.04 | 0.48 | –0.78 to 1.10 | 0.73 |
| Urgent surgical priority | 0.65 | 0.04 | 0.40 | –0.12 to 1.50 | 0.078 |
| Combined CABG | 0.28 | 5.59 | 9.89 | –2.84 to 21.5 | 0.55 |
| Surgery on thoracic aorta | 1.11 | 0.05 | 0.76 | –0.45 to 2.55 | 0.086 |
| Prosthetic valve endocarditis | 0.37 | 0.01 | 0.50 | –0.60 to 1.29 | 0.44 |

CABG indicates coronary artery bypass grafting; CCS indicates Canadian Cardiovascular Society; eGFR, estimated glomerular filtration rate; EuroSCORE, European System for Cardiac Operative Risk Evaluation; NYHA, New York Heart Association; preop., preoperative; ROC, receiver operating characteristic; sPAP, systolic pulmonary artery pressure.

*All variables with a P<0.1 by univariable analysis were included in the model.
†The best discriminatory value for in-hospital mortality by ROC analysis.
‡The creatinine clearance rate, calculated according to the Cockcroft–Gault formula, was used to estimate GFR.
§The definitions and cut-off values are those used for the EuroSCORE II.5

DOI: 10.1161/JAHA.116.004806

The AEPEI Score  Gatti et al

ORIGINAL RESEARCH

by guest on August 4, 2017http://jaha.ahajournals.org/Downloaded from
fungi and multidrug resistant Gram-negative bacteria. Although 3 surgical features (urgent priority, combined coronary surgery, and surgery on thoracic aorta) and 1 endocarditis-related feature (prosthetic valve endocarditis) were found to be related (P<0.1) to in-hospital death by univariable analysis, they were not confirmed as risk factors by multivariable analyses. Contrary to other previous risk prediction models, the variable "prosthetic valve endocarditis" was not found to be an independent risk factor for postoperative in-hospital death in either of the AEPEI scores. Our data do not provide any firm evidence to explain this discrepancy. No intraoperative features were associated with increased postoperative death, even when a composite variable, such as large intracardiac destruction, was considered. In our opinion, this is a strong point of the AEPEI score. Every practitioner is indeed well aware that results of combined cardiac operations in critically ill patients and the treatment of complex intracardiac lesions can be dependent on the surgeon’s experience and expertise, which are both difficult to measure. Despite the existence of some differences between the Italian and French patients of the study, such as the

### Table 12. The AEPEI Score, the Original Model: Contingency Table for the Hosmer–Lemeshow Test for Logistic Regression (n=161)

| Group | Death | Expected | Observed | Expected | Observed | Total |
|-------|-------|----------|----------|----------|----------|-------|
| 1     | 1     | 0.8      | 21       | 21.2     | 22       |
| 2     | 0     | 0.2      | 3        | 2.8      | 3        |
| 3     | 5     | 5.0      | 76       | 76.0     | 81       |
| 4     | 3     | 1.7      | 10       | 11.3     | 13       |
| 5     | 1     | 2.7      | 14       | 12.3     | 15       |
| 6     | 4     | 4.1      | 12       | 11.9     | 16       |
| 7     | 7     | 6.6      | 4        | 4.4      | 11       |

AEPEI indicates Association pour l’Etude et la Prévention de l’Endocardite Infectieuse.

### Table 13. The AEPEI Score, the Alternate Model: Contingency Table for the Hosmer–Lemeshow Test for Logistic Regression (n=361)

| Group | Death | Expected | Observed | Expected | Observed | Total |
|-------|-------|----------|----------|----------|----------|-------|
| 1     | 6     | 8.5      | 153      | 150.5    | 159      |
| 2     | 6     | 6.5      | 55       | 54.5     | 61       |
| 3     | 11    | 8.9      | 41       | 43.1     | 52       |
| 4     | 17    | 13.1     | 30       | 33.9     | 47       |
| 5     | 16    | 19.0     | 26       | 23.0     | 42       |

AEPEI indicates Association pour l’Etude et la Prévention de l’Endocardite Infectieuse.

---

**Figure 2.** External validation of the AEPEI score in a validation sample of 161 patients: discriminatory power. AEPEI indicates Association pour l’Etude et la Prévention de l’Endocardite Infectieuse; AUC, area under the receiver-operating characteristic curve.

**Figure 3.** AEPEI score discriminatory power: the original 5-variable model vs the alternate 3-variable model. AEPEI indicates Association pour l’Etude et la Prévention de l’Endocardite Infectieuse; AUC, area under the receiver operating characteristic curve.
preoperative characteristics of patients, surgical data, and endocarditis-related features, there was no significant difference in the discriminatory power of the AEPEI score between the 2 series of patients. Besides, the Italian series included patients operated on between 2000 and 2015. This could imply that the score works well even in populations of patients with different rates of comorbidities from other institutions, and operated on in different historical periods. Obviously, these hypotheses remain to be verified by new studies that take into consideration the impact on outcomes of the use of different surgical methods, different rates of use of surgical techniques, and different perioperative management of patients.

Overall, the performance of the predictive models considered and derived from large populations of patients from North America, that is, STS risk score for IE and OPR score, was lower than the European models. This could stress the concept that outcomes postsurgery for IE are influenced by epidemiological features both of the patient and the involved pathogen.

**Study Limitations**

The primary limitation of the present study was the small size of the sample. Actually, because the study patients were only 361, it is not surprising that only 5 variables were significant upon multivariable modeling. There may be indeed insufficient power to determine higher dimensional models. However, this is a problem common also to 2 other existing scoring systems that are being used to predict early mortality postsurgery for IE, namely the PALSUSE and the De Feo score, and more

### Table 14. Bootstrap Analysis of the Logistic Regression Model From Which the Alternate Model of the AEPEI Score was Generated

| Variable                                        | A       | Bias   | SE    | 95% CI       | P Value |
|------------------------------------------------|---------|--------|-------|--------------|---------|
| Age >70 years                                   | 0.16    | <0.001 | 0.47  | -0.81 to 1.05| 0.7     |
| BMI >27 kg/m²                                   | 0.65    | 0.04   | 0.41  | -0.13 to 1.55| 0.08    |
| eGFR <50 mL/min                                 | 1.16    | 0.14   | 0.41  | 0.49 to 2.13  | <0.01   |
| Dialysis                                        | 0.38    | -0.08  | 1.66  | -1.68 to 2.18 | 0.66    |
| NYHA class IV                                   | 0.73    | 0.06   | 0.41  | -0.004 to 1.66 | 0.05    |
| CCS class 4                                     | 0.18    | -0.01  | 0.74  | -1.40 to 1.53 | 0.8     |
| Left ventricular ejection fraction, 30% to 50%  | 0.25    | -0.01  | 0.47  | -0.75 to 1.14 | 0.54    |
| Coronary artery disease                         | 0.38    | -6.50  | 10.1  | -20.2 to 3.13 | 0.44    |
| Previous cardiac surgery                        | 0.26    | 0.01   | 0.57  | -0.82 to 1.44 | 0.6     |
| Critical state                                  | 0.91    | 0.08   | 0.53  | -0.07 to 2.07 | 0.05    |
| Length of the preop. hospital stay <10 days     | 0.06    | 0.05   | 0.44  | -0.76 to 0.99 | 0.89    |
| Urgent surgical priority                        | 0.59    | -0.01  | 0.44  | -0.25 to 1.42 | 0.14    |
| Combined CABG                                   | 0.23    | 6.51   | 10.1  | -2.68 to 21.1 | 0.53    |
| Surgery on thoracic aorta                       | 0.94    | 0.01   | 0.76  | -0.70 to 2.41 | 0.13    |
| Prosthetic valve endocarditis                   | 0.37    | <0.001 | 0.49  | -0.66 to 1.28 | 0.4     |

CABG indicates coronary artery bypass grafting; CCS indicates Canadian Cardiovascular Society; eGFR, estimated glomerular filtration rate; EuroSCORE, European System for Cardiac Operative Risk Evaluation; NYHA, New York Heart Association; preop., preoperative; ROC, receiver operating characteristic; sPAP, systolic pulmonary artery pressure.

*All variables with a $P<0.1$ by univariable analysis except $sPAP >55$ mm Hg were included in the model.

†The best discriminatory value for in-hospital mortality by ROC analysis.

‡The creatinine clearance rate, calculated according to the Cockcroft-Gault formula, was used to estimate GFR.

§The definitions and cut-off values are those used for the EuroSCORE II.

### Table 15. The AEPEI Score, the Alternate Model: Contingency Table for the Hosmer–Lemeshow Test for Logistic Regression ($n=161$)

| Group | Death  | Survival | Total |
|-------|--------|----------|-------|
|       | Observed | Expected |       |
| 1     | 10      | 9.0      | 110   |
| 2     | 1       | 3.1      | 21    |
| 3     | 10      | 8.9      | 9     |

AEPEI indicates Association pour l’Etude et la Prévention de l’Endocardite Infectieuse.
Conclusions

Nonspecific scoring systems derived from large populations of patients are being used worldwide to predict adverse events after cardiac surgery, even in patients with IE. For this difficult subset of patients, however, risk stratification is of the utmost importance not only to aid the surgeon’s decision making, but also to ensure true informed consent for patients and their family, and to allow comparative assessment of quality of care. Specific and simple predictive systems, such as the AEPEI score developed and validated here, could be useful to achieve these objectives. However, further larger validation studies are necessary before introducing the AEPEI score into the clinical practice.

Appendix

The Association pour l’Etude et la Prevention de l’Endocadite Infectieuse (AEPI) Study Group Members

Main investigators: B. Hoen and X. Duval; F. Alla, A. Bouvet, S. Briancon, E. Cambau, M. Celard, C. Chirouze, N. Danchin, T. Doco-Lecompte, F. Delahaye, J. Etienne, B. Iung, V. Le Moing, J. F. Obadia, C. Leport, C. Payart, M. Revest, C. Selton-Suty, C. Strady, P. Tattevin, and F. Vandenesch.

Coordinating investigators in the study areas: Y. Bernard, S. Chocron, C. Chirouze, B. Hoen, P. Plesiat, I. Abouliatim, C. De Place, P. Tattevin, M. Revest, P. Y. Donnio, F. Alla, J. P. Carteaux, T. Doco-Lecompte, C. Lion, N. Aissa, C. Selton-Suty, B. Baehrel, R. Jaussaud, P. Nazeyrollas, C. Strady, V. Vernet, E. Cambau, X. Duval, B. Iung, P. Natal, C. Chidiac, M. Celard, F. Delahaye, J. F. Obadia, F. Vandenesch, H. Aumaître, J. M. Frappier, V. Le Moing, E. Oziol, A. Soto, and C. Sportouch.

Centre National de Référence des Staphylocoques: F. Vandenesch, M. Celard, and M. Bes.

Investigators: P. Abassade, E. Abrial, C. Aacar, N. Aissa, J. F. Alexandra, N. Amireche, D. Amrein, P. Andre, M. Appriou, M. A. Arnould, P. Assayag, A. Atoui, F. Aziza, N. Baille, N. Bajolle, P. Battistella, S. Baumard, A. Ben Ali, J. Bertrand, S. Bialek, M. Bois Grosse, M. Boixados, F. Borlot, A. Bouchachi, O. Bouche, S. Bouchemal, J. L. Bourdon, A. Bouvet, L. Brasme, F. Bricaire, E. Brochet, J. F. Brunzt, A. Cady, J. Calhon, M. P. Caplan, B. Carette, J. P. Carteaux, O. Cartry, C. Cazorla, M. Celard, H. Chamagne, H. Champagne, G. Chanques, J. Chastre, B. Chevalier, C. Chirouze, S. Chocron, F. Chometon, C. Christophe, A. Cohen, N. Colin de Verdiere, N. Danchin, V. Daneluzzi, L. David, P. De Lendequette, F. Delahaye, V. Delcey, P. Deleuze, E. Donal, X. Duval, B. Deroure, V. Descotes-Genon, K. Didier Petit, A. Dinh, V. Doat, F. Duchene, F. Duhoxm, M. Dupont, S. Ederhy, O. Epaulard, M. Evest, J. F. Faucher, B. Fantin, E. Fauveau, T. Ferry, M. Fillod, T. Floch, T. Fraisse, J. M. Frapiere, L. Freysz, B. Fumery, B. Gachot, S. Gallien, I. Gandjbach, P. Garcon, A. Gaubert, J. L. Genoud, S. Ghiglione, C. Godreul, A. Grentzinger, L. Groben, D. Ghessi, P. Guéret, A. Hagege, N. Hammoudi, F. Heliot, P. Henry, S. Herson, B. Hoen, P. Hourie, E. Hustache-Mathieu, O. Huttin, S. Imbert, B. Iung, S. Jaureguiberry, M. Kaaki, A. Konde, J. M. Kuhn, S. Kural Menasche, A. Lafitte, B. Lafon, F. Lanterneir, V. Le Chenaux, V. Le Moing, C. Lechiche, S. Lefèvre-Thibaut, A. Lefort, A. Leguerrier, J. Lemoine, L. Lepege, C. Leport, C. Lepoussé, J. Leroy, P. Lesprite, L. Letarchant, D. Loisance, G. Loncar, C. Lorentz, P. Mabo, I. Magnin-Pouill, T. May, A. Makinson, H. Man, M. Mansouri, O. Marxen, J. P. Maroni, V. Masse, F. Maurier, M. C. Meyohas, P. L. Michel, C. Michelet, F. Mechaï, O. Merceron, D. Messika-Zeitoun, Z. Metref, V. Meyssonier, C. Mezher, S. Micheli, M. Monsigny, S. Mouly, B. Mourvillier, O. Nallet, P. Natal, P. Nazeyrollas, V. Noel, J. F. Obadia, E. Oziol, T. Papo, B. Payet, A. Pelletier, P. Perez, J. S. Petit, F. Philippart, E. Piet, C. Plainvert, B. Popovic, J. M. Porste, P. Pradier, R. Ramadan, M. Revest, J. Richemond, M. Rodermann, M. Roncato, I. Roigt, O. Ruyer, M. Saada, J. Schwartz, C. Selton-Suty, M. Simon, B. Simorre, S. Skalli, F. Spatz, C. Strady, J. Sudrial, L. Tartiere, A. Terrier De La Chaise, M. C. Thiercelin, D. Thomas, M. Thomas, L. Toko, F. Tournoux, A. Tristan, J. L. Trouillet, L. Tual, A. Vahanian, F. Verdier, V. Vernet Garnier, V. Vidal, P. Weyne, M. Wolff, A. Wynckel, N. Zannad, and P. Y. Zinzius.

Acknowledgments

The present authors sincerely thank Fiona Ecarnot (EA3920, University Hospital Jean Minjoz, Besançon, France), for editorial...
assistance and critical revision, and Mamadou Toure, statistician and data manager at Department of Thoracic and Cardiovascular Surgery of the University Hospital Jean Minjoz of Besançon, France, for his contribution to statistical analysis of this study.

**Sources of Funding**

Dr Duval reports grants from Pfizer Inc (New York, NY) outside the submitted work.

**Disclosures**

None.

**References**

1. Cahill TJ, Prendergast BD. Infective endocarditis. Lancet. 2016;387:882–893.
2. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, Euroscores II Group, et al. 2015 ESC guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36:3075–3128.
3. Revilla A, López J, Vilacosta I, Villacorta E, Rollán MJ, Eschevarría JR, Carrascal Y, Di Stefano S, Fulquet E, Rodríguez E, Fiz L, San Román JA. Clinical and prognostic profile of patients with infective endocarditis who need urgent surgery. Eur Heart J. 2007;28:65–71.
4. Ad N, Holmes SD, Patel J, Pritchard G, Shuman DJ, Halpin L. Comparison of EuroSCORE II, Original EuroSCORE, and the Society of Thoracic Surgeons Risk Score in Cardiac Surgery Patients. Ann Thorac Surg. 2016;102:573–579.
5. Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, Lockwoodm U. EuroScore II. Eur J Cardiothorac Surg. 2012;41:734–744.
6. Roques F, Michel P, Goldstone AR, Nashef SA. The logistic EuroSCORE. Eur Heart J. 2003;24:882–883.
7. Tu JF, Jaglal SB, Naylor CD. Multicenter validation of a risk index for mortality, intensive care unit stay, and overall hospital length of stay after cardiac surgery. Steering Committee of the Provincial Adult Cardiac Care Network of Ontario. Circulation. 1995;91:677–684.
8. Madeira S, Rodríguez R, Traíhalo A, Santos M, Almeida C, Marques M, Ferreira J, Raposo L, Neves J, Mendes M. Assessment of perioperative mortality risk in patients with infective endocarditis undergoing cardiac surgery: performance of the EuroSCORE I and II logistic models. Interact Cardiovasc Thorac Surg. 2016;22:141–148.
9. Patrat-Delon S, Rouzel A, Gacouin A, Revet M, Flécher E, Fouquet O, Le Tufo Y, Lerolle N, Tattevin P, Taddei JM. EuroSCORE II underestimates mortality after cardiac surgery for infective endocarditis. Eur J Cardiothorac Surg. 2016;49:944–951.
10. Wang TK, Wang MT, Pemberton J. Risk scores and surgery for infective endocarditis: a meta-analysis. Int J Cardiol. 2016;222:1001–1002.
11. Wang TK, Oh T, Voss J, Gamble G, Kang N, Pemberton J. Comparison of contemporary risk scores for predicting outcomes after surgery for infective endocarditis. Heart Vessels. 2015;30:227–234.
12. Grant SW, Hickey GL, Dimarikis I, Cooper G, Jenkins DP, Upul R, Buchan I, Bridgewater B. Performance of the EuroSCORE models in emergency cardiac surgery. Circ Cardiovasc Qual Outcomes. 2013;6:178–185.
13. Mestres CA, Castro MA, Bernabéu E, Josa M, Cartanà R, Pomar JL, Miró JM, Mulet J, Hospital Clínic Cardiovascular Endocarditis Study Group, Preoperative risk stratification in infective endocarditis. Does the EuroSCORE model work? Preliminary results. Eur J Cardiothorac Surg. 2007;32:281–285.
14. Martínez-Sellés M, Muñoz P, Arnáiz A, Moreno M, Gálvez J, Rodríguez-Roda J, de Alarcón A, García Cabrera E, Farínas MC, Miró JM, Monteso M, Moreno A, Ruiz-Morales J, Goenaga MA, Bouza E, Spanish Collaboration on Endocarditis – Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España (GAMES). Valve surgery in active infective endocarditis: a simple score to predict in-hospital prognosis. Int J Cardiol. 2014;175:133–137.
15. De Feo M, Cotrufo M, Caroza A, De Santo LS, Amendolara F, Giordano S, Delia Ratta EE, Nappi G, Delia Corte A. The need for a specific risk prediction system in native valve infective endocarditis surgery. Sci World J. 2012;2012:30751.
16. Gaca JG, Sheng S, Daneshmand MA, O’Brien S, Rankin JS, Brennan JM, Hughes GC, Glower DD, Gammie JS, Smith PK. Outcomes for endocarditis surgery in North America: a simplified risk scoring system. J Thorac Cardiovasc Surg. 2011;141:98–106.e1-2.
17. Selton-Suty C, Cèlard M, Le Moing V, Doco-Lecompte T, Chirouze C, Jung B, Strady C, Revet M, Vandenesch F, Bouvet A, Delahaye F, Alla F, Duval X, Hoen B; APEFI Study Group. Preeminen of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis. 2012;54:1230–1239.
18. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med. 1994;96:200–209.
19. Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, Reilly JP, Zoghbi G, Holper E, Stone GW. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol. 2013;62:1563–1570.
20. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2:1–138.
21. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999;20:250–278.
22. Pescina MJ, D’Agostino RB, Pescina KM, Janssens AC, Greenland P. Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol. 2012;176:473–481.
23. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19:716–723.
**Table S1.** The variables entered in the analysis.

| Group                                | Variable                      | Cut-points and subsets       |
|--------------------------------------|-------------------------------|------------------------------|
| Baseline characteristics of patients | Age (years)                   | <60, 60–70, >70              |
|                                      | Female sex                    |                              |
|                                      | Hypertension                  |                              |
|                                      | Current smoker                |                              |
|                                      | Body mass index (kg/m$^2$)    | >27*                         |
|                                      | Diabetes mellitus             | Diabetes on insulin          |
|                                      | Anemia†                       |                              |
|                                      | White blood cell (10$^3$/mm$^3$)|                              |
|                                      | C-reactive protein (mg/l)     |                              |
|                                      | Poor mobility‡                |                              |
|                                      | Chronic lung disease‡         |                              |
|                                      | eGFR (ml/min)§                | >85, 50–85, <50‡             |
|                                      | Dialysis                      |                              |
|                                      | Extracardiac arteriopathy‡    |                              |
| Parameter                              | Values                                      |
|----------------------------------------|---------------------------------------------|
| NYHA class                             | I, II, III, IV                              |
| CCS class                              | 4                                           |
| Recent myocardial infarction‡          |                                             |
| Left ventricular ejection fraction (%)  | >50, 30–50, 20–30, <20‡                    |
| Pulmonary artery pressure, systolic (mmHg) | <35, 35–55, ≥55‡                          |
| Coronary artery disease                |                                             |
| Previous cardiac surgery               |                                             |
| Critical state‡                        |                                             |
| Length of the preoperative hospital stay (days) | >10*                                     |
| Era||| 2000–2005, 2006–2010, 2011–2015 |

**Surgical features**

| Reason for surgery                      | Refractory heart failure due to valvular dysfunction |
|-----------------------------------------|-------------------------------------------------------|
| Persistent infection                    |                                                       |
| Embolism (and recurrent embolism)      |                                                       |
| Perivalvular complications#             |                                                       |
| Surgical priority‡ | Elective |
|--------------------|----------|
|                    | Urgent   |
|                    | Emergency|
|                    | Salvage  |

| Valve involvement | Aortic |
|-------------------|--------|
|                   | Mitral |
|                   | Tricuspid |
|                   | Multivalvular |

| Large intracardiac destruction | Extensive valve destruction |
|--------------------------------|-----------------------------|
|                                | Perivalvular complications  |
|                                | Multivalvular involvement   |

| Weight of the intervention‡ | Combined CABG |
|-----------------------------|---------------|
|                             | Single non-CABG |
| Endocarditis-related features | Type of endocarditis       | Causal agents                                      |
|------------------------------|---------------------------|---------------------------------------------------|
|                              | Active or treated‡        | Streptococcus species                              |
|                              | Native valve              | Staphylococcus aureus                              |
|                              | Prosthetic valve          | Coagulase-negative Staphylococci                   |
|                              | Intracardiac device or other side | Enterococcus species                              |
| Surgery on thoracic aorta    |                           | Gram-negative bacteria                             |
|                              |                           | Fungi                                             |
|                              |                           | Not identified                                     |
*The best discriminative value for hospital mortality by ROC analysis.
†Defined as haemoglobin <12 g/dl for women and <13 g/dl for men.
‡The definitions and the cut-points are those used for the EuroSCORE II (Suppl. Ref. 1).
§The creatinine clearance rate, calculated according to the Cockcroft-Gault formula, was used to estimate eGFR.
||Only the Italian study patients are considered for this analysis.

#Perivalvular leak, annular or aortic abscess, sinus of Valsalva aneurysm, aortic fistula, and prosthetic valve detachment.

CABG=coronary artery bypass grafting; CCS=Canadian Cardiovascular Society; EuroSCORE=European System for Cardiac Operative Risk Evaluation; eGFR=estimated glomerular filtration rate; NYHA=New York Heart Association; ROC=receiver-operating characteristic curve
Table S2. Baseline characteristics of patients (n=361)*

| Variable                         | Total       | In-hospital dead | Alive       | p-Value |
|----------------------------------|-------------|------------------|-------------|---------|
|                                  | (n=361)     | (n=56)           | (n=305)     |         |
| Age (years)                      | 59.1±15.4   | 62.0±15.7        | 58.6±15.3   | 0.13    |
| <60                              | 169 (46.8)  | 16 (28.6)        | 153 (50.2)  |         |
| 60–70                            | 97 (26.9)   | 18 (32.1)        | 79 (25.9)   |         |
| >70                              | 95 (26.3)   | 22 (39.3)        | 73 (23.9)   |         |
| Female sex                       | 76 (21.1)   | 15 (26.8)        | 61 (20.0)   | 0.25    |
| Hypertension                     | 111 (30.7)  | 18 (32.1)        | 93 (30.5)   | 0.81    |
| Current smoker                   | 65 (18.0)   | 6 (10.7)         | 59 (19.3)   | 0.12    |
| Body mass index (kg/m²)          | 25.4±4.9    | 26.7±5.8         | 25.1±4.7    | 0.026   |
| >27†                             | 95 (26.3)   | 21 (37.5)        | 74 (24.3)   | 0.039   |
| Diabetes                         | 70 (19.4)   | 10 (17.9)        | 60 (19.7)   | 0.75    |
| Diabetes on insulin              | 27 (7.5)    | 6 (10.7)         | 21 (6.9)    | 0.32    |
| Anemia‡                          | 284 (81.7)  | 50 (89.3)        | 245 (80.3)  | 0.13    |
| White blood cell (10³/mm³)       | 14.9 ± 10.5 | 15.3 ± 6.7       | 14.8 ± 11.1 | 0.75    |
| C-reactive protein (mg/l)        | 140.4±85.5  | 151.6±66.9       | 138.4±88.4  | 0.29    |
| Poor mobility§                   | 20 (5.5)    | 5 (8.9)          | 15 (4.9)    | 0.23    |
| Chronic lung disease§            | 33 (9.1)    | 7 (12.5)         | 26 (8.5)    | 0.34    |
| eGFR (ml/min)||                   | 68.8±36.1    | 47.1±31.2        | 72.8±35.6   | <0.0001 |
| >85§                             | 99 (27.4)   | 5 (8.9)          | 94 (30.8)   |         |
| 50–85§                           | 141 (39.1)  | 14 (25.0)        | 127 (41.6)  |         |
| <50§                             | 121 (33.5)  | 37 (66.1)        | 84 (27.5)   |         |
| Dialysis                         | 15 (4.2)    | 5 (8.9)          | 10 (3.3)    | 0.066   |
| Extracardiac arteriopathy§       | 50 (13.9)   | 10 (17.9)        | 40 (13.1)   | 0.35    |
| NYHA class                       |             |                  |             | <0.0001 |
| Class | CCS class 4 | Recent myocardial infarction§ | Left ventricular ejection fraction (%) | Pulmonary artery pressure, systolic (mmHg) | Coronary artery disease | Previous cardiac surgery | Critical state§ | Length of the preop. hospital stay (days) | Era** |
|-------|-------------|-------------------------------|----------------------------------------|-------------------------------------------|------------------------|------------------------|-----------------|------------------------------------------|-------|
| I     | 105 (29.1)  | 7 (12.5)                      | 98 (32.1)                              | <0.001                                    | 0.015                  | 0.29                   | 0.05            | 0.02                                     | 0.054 |
| II    | 37 (10.2)   | 1 (1.8)                       | 36 (11.8)                              |                                           |                        |                        |                 |                                          |       |
| III   | 83 (23)     | 14 (25.0)                     | 69 (22.6)                              |                                           |                        |                        |                 |                                          |       |
| IV    | 136 (37.7)  | 34 (60.7)                     | 102 (33.4)                             |                                           |                        |                        |                 |                                          |       |
| CCS class 4 | 23 (6.4) | 8 (14.3)                      | 15 (4.9)                               |                                           |                        |                        |                 |                                          |       |
| Recent myocardial infarction§ | 1 (0.3) | 0                            | 1 (0.3)                               | 1                                         |                        |                        |                 |                                          |       |
| Left ventricular ejection fraction (%) | 56.6±3.5 | 54.6±12.1                    | 57.2±10.3                              | 0.29                                      |                        |                        |                 |                                          |       |
| >50§  | 289 (80.1)  | 39 (69.6)                     | 250 (82.0)                             |                                           |                        |                        |                 |                                          |       |
| 30–50§ | 67 (18.6) | 16 (28.6)                    | 51 (16.7)                              |                                           |                        |                        |                 |                                          |       |
| 20–30§ | 4 (1.1)    | 1 (1.8)                       | 3 (1)                                  |                                           |                        |                        |                 |                                          |       |
| <20§  | 1 (0.3)     | 0                            | 1 (0.3)                                |                                           |                        |                        |                 |                                          |       |
| Pulmonary artery pressure, systolic (mmHg) | <0.0001 |                                |                                       |                                           |                        |                        |                 |                                          |       |
| <35§  | 273 (75.6)  | 44 (78.6)                     | 229 (75.1)                             |                                           |                        |                        |                 |                                          |       |
| 35–55§ | 70 (19.4) | 6 (10.7)                     | 64 (21)                                |                                           |                        |                        |                 |                                          |       |
| >55§  | 18 (5)      | 6 (10.7)                      | 12 (3.9)                               |                                           |                        |                        |                 |                                          |       |
| Coronary artery disease | 43 (11.9) | 11 (19.6)                    | 32 (10.5)                              | 0.052                                     |                        |                        |                 |                                          |       |
| Previous cardiac surgery | 54 (15.0) | 14 (25.0)                    | 40 (13.1)                              | 0.022                                     |                        |                        |                 |                                          |       |
| Critical state§ | 62 (17.2) | 23 (41.1)                    | 39 (12.8)                              | <0.0001                                   |                        |                        |                 |                                          |       |
| Length of the preop. hospital stay (days) | 9 [3–25]# | 7 [4–16]#                    | 10 [3–26]#                              | 0.054                                     |                        |                        |                 |                                          |       |
| <10‡  | 190 (52.6)  | 36 (64.3)                     | 154 (50.5)                             | 0.061                                     |                        |                        |                 |                                          |       |
| Era** |                       |                              |                                        |                                           |                        |                        |                 |                                          | 0.81  |
| 2000–2005 | 40/138 (30) | 7/28 (25)                    | 33/110 (30)                            |                                           |                        |                        |                 |                                          |       |
| 2006–2010 | 43/138(31.1) | 10/28 (35.7)                | 33/110 (30)                            |                                           |                        |                        |                 |                                          |       |
| 2011–2015 | 55/138 (39.9) | 11/28 (39.3)              | 44/110 (40)                            |                                           |                        |                        |                 |                                          |       |
*Unless otherwise stated, values are mean ± standard deviation, or number (percentage).

†The best discriminative value for in-hospital mortality by ROC analysis.

‡Defined as haemoglobin <12 g/dl for women and <13 g/dl for men.

§The definitions and the cut-off values are those used for the EuroSCORE II (Suppl. Ref. 1).

||The creatinine clearance rate, calculated according to the Cockcroft-Gault formula, was used to estimate GFR.

#Median [interquartile range].

**Only the Italian study patients are considered for this analysis.

CCS=Canadian Cardiovascular Society; EuroSCORE=European System for Cardiac Operative Risk Evaluation; eGFR=estimated glomerular filtration rate; NYHA=New York Heart Association;

ROC=receiver-operating characteristic curve
Table S3. Surgical features (n=361)*

| Variable                                | Total (n=361) | In-hospital dead (n=56) | Alive (n=305) | p-Value |
|-----------------------------------------|---------------|-------------------------|---------------|---------|
| **Reason for surgery**                  |               |                         |               |         |
| Refractory heart failure due to valvular dysfunction | 91 (25.2)     | 17 (30.4)               | 74 (24.3)     | 0.33    |
| Persistent infection                    | 46 (12.7)     | 6 (10.7)                | 40 (13.1)     | 0.62    |
| Embolism                                | 164 (45.4)    | 27 (48.2)               | 137 (44.9)    | 0.65    |
| Recurrent                               | 53 (14.7)     | 11 (19.6)               | 42 (13.8)     | 0.25    |
| Perivalvular complications†             | 107 (29.6)    | 19 (33.9)               | 88 (28.9)     | 0.45    |
| **Surgical priority‡**                  |               |                         |               | <0.0001 |
| Elective                                | 133 (36.8)    | 10 (17.9)               | 123 (40.3)    |         |
| Urgent                                  | 184 (51.0)    | 38 (67.9)               | 146 (47.9)    |         |
| Emergency                               | 33 (9.1)      | 7 (12.5)                | 26 (8.5)      |         |
| Salvage                                 | 11 (3)        | 1 (1.8)                 | 10 (3.3)      |         |
| **Valve involvement**                   |               |                         |               |         |
| Aortic                                  | 224 (62.0)    | 34 (60.7)               | 190 (62.3)    | 0.82    |
| Mitral                                  | 167 (46.3)    | 31 (55.4)               | 136 (44.6)    | 0.14    |
| Tricuspid                               | 35 (9.7)      | 4 (7.1)                 | 31 (10.2)     | 0.48    |
| Multivalvular                           | 78 (21.6)     | 15 (26.8)               | 63 (20.7)     | 0.31    |
| Large intracardiac destruction§         | 175 (48.5)    | 32 (57.1)               | 143 (46.9)    | 0.16    |
| **Weight of the intervention‡**         |               |                         |               |         |
| Combined CABG                           | 38 (10.5)     | 10 (17.9)               | 28 (9.2)      | 0.052   |
| Single non-CABG                         | 215 (59.6)    | 28 (50.0)               | 187 (61.3)    | 0.11    |
| Two procedures                          | 128 (35.5)    | 24 (42.9)               | 104 (34.1)    | 0.21    |
| Three procedures                        | 18 (5.0)      | 4 (7.1)                 | 14 (4.6)      | 0.49    |
Surgery on thoracic aorta

|            | 24 (6.6) | 7 (12.5) | 17 (5.6) | 0.075 |

*Values are mean ± standard deviation, or number (percentage).

†Perivalvular leak, annular or aortic abscess, sinus of Valsalva aneurysm, aortic fistula and prosthetic valve detachment.

‡The definitions are those used for the EuroSCORE II (Suppl. Ref. 1).

§Defined as extensive valve destruction, perivalvular complications or multivalvular involvement.

CABG=coronary artery bypass grafting; EuroSCORE=European System for Cardiac Operative Risk Evaluation
Table S4. Endocarditis-related features (n=361)*

| Variable                        | Total (n=361) | In-hospital dead (n=56) | Alive (n=305) | p-Value |
|---------------------------------|---------------|-------------------------|---------------|---------|
| Endocarditis                    |               |                         |               |         |
| Active†                         | 275 (76.2)    | 38 (67.9)               | 237 (77.7)    | 0.11    |
| Treated†                        | 86 (23.8)     | 18 (32.1)               | 68 (22.3)     |         |
| Type of endocarditis            |               |                         |               |         |
| Native valve                    | 285 (78.9)    | 39 (69.6)               | 246 (80.7)    | 0.063   |
| Prosthetic valve                | 68 (18.8)     | 16 (28.6)               | 52 (17)       | 0.043   |
| Intracardiac device or other side | 48 (13.3)  | 10 (17.9)               | 38 (12.5)     | 0.27    |
| Causal agents                   |               |                         |               |         |
| Streptococcus species           | 134 (37.1)    | 13 (23.2)               | 121 (39.7)    |         |
| Staphylococcus aureus           | 72 (19.9)     | 13 (23.2)               | 59 (19.3)     |         |
| Coagulase-negative              | 33 (9.1)      | 8 (14.3)                | 25 (8.2)      |         |
| Staphylococci                   | 37 (10.2)     | 7 (12.5)                | 30 (9.8)      |         |
| Enterococcus                    | 15 (4.2)      | 2 (3.6)                 | 13 (4.3)      |         |
| Gram-negative bacteria          | 4 (1.1)       | 2 (3.6)                 | 2 (0.7)       |         |
| Fungi                           | 66 (18.3)     | 11 (19.6)               | 55 (18)       |         |
| Not identified                  |               |                         |               |         |

*Number (percentage).

†The definitions are those used for the EuroSCORE II (Suppl. Ref. 1).

EuroSCORE=European System for Cardiac Operative Risk Evaluation
Supplemental Reference:

1. Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, Lockowandt U. EuroSCORE

II. *Eur J Cardiothorac Surg*. 2012;41:734-744.
Simple Scoring System to Predict In–Hospital Mortality After Surgery for Infective Endocarditis

Giuseppe Gatti, Andrea Perrotti, Jean-François Obadia, Xavier Duval, Bernard Iung, François Alla, Catherine Chirouze, Christine Selton-Suty, Bruno Hoen, Gianfranco Sinagra, François Delahaye, Pierre Tattevin, Vincent Le Moing, Aniello Pappalardo, Sidney Chocron and The Association for the Study and Prevention of Infective Endocarditis Study Group-Association pour l'Étude et la Prévention de l'Endocardite Infectieuse (AEPEI)

J Am Heart Assoc. 2017;6:e004806; originally published July 20, 2017; doi: 10.1161/JAHA.116.004806

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://jaha.ahajournals.org/content/6/7/e004806